Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Receptor Occupancy & Off-Target Profiling Service
Are you currently facing complex safety challenges, extended timelines, or unexpected toxicities in your preclinical drug development? At Creative Biolabs, our NHP Receptor Occupancy & Off-Target Profiling In Vitro Cell-Based Safety Assays are engineered to solve these critical problems. We help you accelerate drug discovery and minimize risks by providing early, comprehensive insights into drug-target interactions, leveraging our advanced expertise and state-of-the-art platforms. Experience confidence in your preclinical pipeline with our precise and reliable data.
Introduction to NHP Safety Assays
What Our Service Is
Creative Biolabs' service provides a critical in vitro assessment of drug candidates, specifically evaluating how a compound interacts with its intended target and other, unintended targets. By using cells derived from non-human primates (NHPs), we offer a model that is genetically and physiologically highly similar to humans, providing more clinically relevant safety data than traditional rodent models. Our services are essential for:
- Dose Optimization: Determining the optimal drug concentration needed to achieve the desired receptor occupancy for therapeutic effect while minimizing adverse events.
- Lead Candidate Selection: Differentiating between drug candidates based on their on-target selectivity and off-target safety profiles.
- Preclinical Risk Mitigation: Identifying potential toxicities or side effects early in the development pipeline before costly and time-consuming in vivo studies.
Why Choose Us?
Choosing Creative Biolabs means choosing a partner committed to de-risking your preclinical pipeline. We transform the pain points of uncertainty and potential failure into the benefits of informed decision-making and accelerated progress. Our NHP-based assays provide a high-fidelity predictive model, offering a significant advantage in moving from preclinical to clinical stages. By identifying and mitigating safety concerns early, we save you valuable time and financial resources, enabling you to focus on the most promising candidates with confidence.
Distributed under Unsplash License, from Unsplash.
Key Benefits of Our Service
Creative Biolabs' NHP Receptor Occupancy & Off-Target Profiling service is built on a foundation of unique strengths designed to give your project a competitive edge. Our dedicated team and advanced platforms deliver a level of detail and responsiveness that sets us apart.
- Exceptional Response Speed: Our streamlined processes and dedicated resources ensure a rapid turnaround time for your screening projects, allowing you to quickly iterate and move forward.
- Comprehensive NHP Resources: We maintain access to a diverse range of NHP cell types, including Peripheral Blood Mononuclear Cells (PBMCs) and other tissue-specific cell lines, providing a robust and flexible platform to model a drug's potential effects across multiple organ systems.
- Unmatched Customization: Our assays can be tailored to meet the specific requirements of your project. Whether you need a small, focused panel or a comprehensive, broad-spectrum screen, we can design a study that addresses your unique safety questions.
- Depth of Reporting: Our deliverables include detailed, in-depth reports that go beyond raw data. We provide expert analysis, model annotations, and clear conclusions, giving you the actionable insights needed to guide your next steps.
How Creative Biolabs' Safety Assays Can Assist Your Project?
Our NHP In Vitro Safety Assays provide specific, tangible solutions for your drug development needs, delivering clear answers to complex safety questions. We offer a proven workflow that is both rigorous and transparent, ensuring you have a complete understanding of your drug candidate's safety profile.
01
Required Starting Materials
02
Project Scoping & Assay Design
03
Cell Culture & Preparation
04
Dose-Response & Binding Assays
05
Off-Target Panel Screening
06
Data Analysis & Report Generation
Key Deliverables
Our commitment to transparency and detail is reflected in our comprehensive deliverables, which include:
- Detailed Lab Reports: A full report with executive summary, methodology, results, figures, and expert analysis.
- Complete Raw Data: All raw data files from the flow cytometry or binding assays for your reference and internal analysis.
- Model Annotations: Detailed notes and annotations on the cell models used, ensuring complete reproducibility.
- Summary of Findings: A concise, easy-to-understand summary highlighting key receptor occupancy and off-target binding data.
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: Over 50,000 samples analyzed per year.
- Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
- Study Pass Rate: 99%+ success rate in meeting study endpoints.
Our Valued Partners
Frequently Asked Questions
Q: Can your assays handle both small molecules and complex biologics like antibodies?
A: Absolutely. Our platforms are flexible and robust, designed to effectively screen both small-molecule drugs and large-molecule biologics. We can tailor the assay conditions and detection methods to ensure accurate and reliable data for your specific compound, regardless of its size or complexity.
Q: How do you handle potential false positives in the off-target screening process?
A: We use a multi-tiered approach to address potential false positives. Our initial high-throughput screens are followed by confirmatory assays for any compounds that show an initial hit. This rigorous validation process ensures that the data you receive is accurate and actionable, allowing you to confidently prioritize your drug candidates.
Q: What if I have a unique or proprietary target? Can you still help?
A: Our team of experts has extensive experience in developing custom assays for novel targets. We will work closely with you to design a bespoke screening strategy that meets the unique requirements of your project, ensuring we can provide the precise safety data you need.
Q: How does early-stage off-target profiling benefit my project's overall timeline and budget?
A: Identifying potential safety issues early with our in vitro assays is a cost-effective strategy. By eliminating unsafe candidates before they enter expensive and time-consuming in vivo or clinical trials, you save significant resources and prevent costly project failures. This proactive approach streamlines your development timeline and maximizes your investment.
Contact Us
Creative Biolabs' NHP Receptor Occupancy & Off-Target Profiling In Vitro Cell-Based Safety Assays offer a powerful solution for de-risking your preclinical pipeline. We combine the predictive power of NHP models with our state-of-the-art platforms and expert analysis to provide clear, actionable safety data. To learn more about our NHP safety assays or to discuss your specific project needs, please contact our expert team.